Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Gastroenterology. 2014 Apr 22;147(2):453–462.e7. doi: 10.1053/j.gastro.2014.04.021

Figure 5.

Figure 5

Antiviral activity of LDV against resistance-associated variants (RAVs). (A) Antiviral resistance (fold-increase in EC50) and relative replication fitness of Y93H, Q30R, and L31V mutants compared with parental H77S.3 virus (‘wt’) were determined in GLuc and FFU reduction assays at 72 hrs (wt fitness set arbitrarily at 100). ‘n.d.’ = not determined (precluded by low fitness). Results shown represent means ± s.d. (B) LDV-mediated inhibition of (top panel) GLuc secretion and (lower panel) infectious virus release at 24, 48, and 72 hrs following addition of drug to L31V virus-infected cells. The antiviral effect against the parental virus (‘wt’) at 72 hrs is shown for comparison.